Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Fortrea Holdings Inc. Common Stock

FTRE

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Last trade $19.97
Day change +$0.18 (+0.91%)
Day range $19.48 – $20.57
Volume 1,163,095
Market cap $1.91B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.91B
Price / earnings
—
Price / book
3.59×
Price / sales
0.72×
EV / sales
1.03×
EV / EBITDA
22.13×

Profitability

Earnings per share
-$0.71
Return on assets
-2.51%
Return on equity
-12.91%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.98×
Current ratio
0.97×
Quick ratio
0.97×
Cash ratio
0.22×

Cash flow

Price / cash flow
9.46×
Price / free cash flow
11.3×
Free cash flow
$169M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for FTRE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$691.5M$678.2M$636.5M$660.5M$701.3M$710.3M$651.3M$697M
Cost of revenue$552M$539M$512.9M$529.4M$578.6M$576.8M$534.8M$556.1M
Gross profit$139.5M$139.2M$123.6M$131.1M$122.7M$133.5M$116.5M$140.9M
Selling, general and administrative$103.8M$102.1M$100.5M$103M$106.8M$124.8M$121.8M$148.1M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$124.5M$124.4M$127M$144.7M$131.3M$463.8M$636.6M$196.5M
Operating income$15M$14.8M-$3.4M-$13.6M-$8.6M-$330.3M-$520.1M-$55.6M
Interest expense-$20.2M-$19.3M-$19.1M$0-$22.6M-$23.3M-$22.3M$0
Income before taxes-$3.6M-$1.2M-$12.3M-$35.6M-$28.7M-$370.7M-$548M-$74.9M
Income taxes-$4.2M$12M$11.3M-$3.1M-$12.8M$4.2M$14.9M-$1M
Net income$600K-$13.2M-$23.6M-$32.5M-$15.9M-$374.9M-$562.9M-$61.2M
Net income attributable to common shareholders$600K-$13.2M-$23.6M-$32.5M-$15.9M-$374.9M-$562.9M-$61.2M
EBITDA$35.7M$37.1M$23.1M$28.1M$15.9M$8.7M-$5.3M-$7.2M
Basic earnings per share$0.01-$0.14-$0.25-$0.35-$0.17-$4.14-$6.25-$0.68
Diluted earnings per share$0.01-$0.14-$0.25-$0.35-$0.17-$4.14-$6.25-$0.68

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Fortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass Estimates

Fortrea Holdings Inc. (FTRE) reported Q3 earnings of $0.28 per share, beating consensus estimates of $0.24, and revenues of $691.5 million, exceeding expectations by 3.18%. The company has outperformed the market by 50% year-to-date versus the S&P 500's 13.1% gain. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Fortrea to Participate in Jefferies Global Healthcare Conference

Fortrea (FTRE), a leading global CRO, announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026, with a fireside chat and 1x1 meetings scheduled.

Zacks Investment Research

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex Pharmaceuticals is expected to report Q3 2026 earnings of $4.92 per share (up 2.5% YoY) with revenues of $3.4 billion (up 10.6% YoY) on November 2. The company has a positive Earnings ESP of +4.98% combined with a Zacks Rank #3, suggesting a likely earnings beat. However, past performance shows mixed results with only 2 beats in the last 4 quarters.

GlobeNewswire Inc.

Collaboration entre Fortrea et Omico pour faire progresser le développement de médicaments oncologiques basés sur des biomarqueurs

Fortrea, a leading global contract research organization, has announced a collaboration with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven oncology drug development. The partnership combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve clinical trial planning, site selection, and patient recruitment for targeted cancer therapies in Australia.

GlobeNewswire Inc.

שיתוף פעולה בין Fortrea ל-Omico לקידום פיתוח תרופות אונקולוגיות המבוססות על סמנים ביולוגיים

Fortrea, a leading global clinical research organization, has announced a collaboration with Omico, Australia's leading precision oncology platform, to accelerate biomarker-driven oncology research. The partnership combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve trial design, site selection, and patient recruitment, enabling faster access to relevant clinical trials for cancer patients based on their genomic profiles across Australia.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.